Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2009 1
2011 1
2012 1
2013 1
2018 1
2020 3
2021 2
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Metastatic BRCA-Associated Breast Carcinoma"
Page 1
Molecular basis and therapeutic targets in prostate cancer: A comprehensive review.
Militaru FC, Militaru V, Crisan N, Bocsan IC, Udrea AA, Catana A, Kutasi E, Militaru MS. Militaru FC, et al. Biomol Biomed. 2023 Sep 4;23(5):760-771. doi: 10.17305/bb.2023.8782. Biomol Biomed. 2023. PMID: 37021836 Free PMC article. Review.
The most common genetic syndromes associated with prostate cancer risk are BRCA-associated hereditary breast and ovarian cancer (HBOC) and Lynch syndrome. Local-regional therapy, i.e., surgery is beneficial in early-stage prostate cancer management. Advanced …
The most common genetic syndromes associated with prostate cancer risk are BRCA-associated hereditary breast and ovaria …
Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation.
van Barele M, Akdeniz D, Heemskerk-Gerritsen BAM; Genepso; Andrieu N, Noguès C; HEBON; van Asperen CJ, Wevers M, Ausems MGEM, de Bock GH, Dommering CJ, Gómez-García EB, van Leeuwen FE, Mooij TM; EMBRACE; Easton DF, Antoniou AC, Evans DG, Izatt L, Tischkowitz M, Frost D, Brewer C, Olah E, Simard J, Singer CF, Thomassen M, Kast K, Rhiem K, Engel C, de la Hoya M, Foretová L, Jakubowska A, Jager A, Sattler MGA, Schmidt MK, Hooning MJ. van Barele M, et al. J Natl Cancer Inst. 2023 Nov 8;115(11):1318-1328. doi: 10.1093/jnci/djad116. J Natl Cancer Inst. 2023. PMID: 37369040 Free PMC article.
BACKGROUND: Radiation-induced secondary breast cancer (BC) may be a concern after radiation therapy (RT) for primary breast cancer (PBC), especially in young patients with germline (g)BRCA-associated BC who already have high contralateral BC (CB …
BACKGROUND: Radiation-induced secondary breast cancer (BC) may be a concern after radiation therapy (RT) for primary breast …
Radiation-Associated Secondary Malignancies in BRCA Mutation Carriers Treated for Breast Cancer.
Schlosser S, Rabinovitch R, Shatz Z, Galper S, Shahadi-Dromi I, Finkel S, Jacobson G, Rasco A, Friedman E, Laitman Y, Evron E, Bernstein R, Weiss I, Sklair-Levy M, Ben-David MA. Schlosser S, et al. Int J Radiat Oncol Biol Phys. 2020 Jun 1;107(2):353-359. doi: 10.1016/j.ijrobp.2020.02.020. Epub 2020 Feb 19. Int J Radiat Oncol Biol Phys. 2020. PMID: 32084523 Clinical Trial.
PURPOSE: Radiation therapy (RT), a standard breast cancer (BC) treatment modality, is associated with a small increased risk of in-field second primary malignancy (SPM). ...CONCLUSIONS: In this largest cohort of women treated with radiation therapy for BRCA-assoc …
PURPOSE: Radiation therapy (RT), a standard breast cancer (BC) treatment modality, is associated with a small increased risk of in-fi …
Medical Management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier.
Desai NV, Tung NM. Desai NV, et al. Breast J. 2020 Aug;26(8):1506-1512. doi: 10.1111/tbj.13972. Epub 2020 Jul 6. Breast J. 2020. PMID: 32633033 Review.
Research has demonstrated improved response rates to platinum salts in BRCA-mutated compared with non-BRCA-mutated breast cancer, particularly in the metastatic setting. Additionally, clinical trials of single-agent PARP inhibitors have shown encouraging response ra …
Research has demonstrated improved response rates to platinum salts in BRCA-mutated compared with non-BRCA-mutated breast cancer, par …
Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort.
Ishiyama Y, Shimbo M, Iizuka J, Deshpande G, Tanabe K, Hattori K. Ishiyama Y, et al. PLoS One. 2020 Dec 22;15(12):e0244149. doi: 10.1371/journal.pone.0244149. eCollection 2020. PLoS One. 2020. PMID: 33351846 Free PMC article.
In addition to breast, ovarian, and pancreatic cancers, BRCA1/2 genes have been associated with prostate cancer (PC). ...BRCA1/2-associated FCH was not significantly associated with high Gleason score ( 8). Patients with BRCA-associated FCH were less likely t …
In addition to breast, ovarian, and pancreatic cancers, BRCA1/2 genes have been associated with prostate cancer (PC). ...BRCA1/2-asso …
Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States.
Liede A, Sebby W, Miriyala AKR, Potluri R, Mazumder D, Ghosh A, Papademetriou E, Kilpatrick R, Tyczynski JE. Liede A, et al. BMC Cancer. 2023 Jan 24;23(1):78. doi: 10.1186/s12885-023-10554-6. BMC Cancer. 2023. PMID: 36690978 Free PMC article.
BACKGROUND: Incidence and risk factors for seizures among women with advanced breast cancer (BC) and brain metastases are not well characterized across treatment-related or clinical subtypes. This study leveraged a large real-world dataset to describe incidence and risk fa …
BACKGROUND: Incidence and risk factors for seizures among women with advanced breast cancer (BC) and brain metastases are not well ch …
Machine Learning-Devised Immune-Related lncRNA Signature Panel Predicts the Prognosis and Immune Landscape in Breast Cancer Novel IRLP Signature in BRCA.
Zhu JY, Lyu AQ, Wang ZT, Chan WY, Qin T, Miu KK, Yao HR. Zhu JY, et al. J Immunol Res. 2022 Aug 18;2022:3704798. doi: 10.1155/2022/3704798. eCollection 2022. J Immunol Res. 2022. PMID: 36033386 Free PMC article.
Long noncoding RNAs (lncRNAs) actively participate in breast cancer (BRCA) tumorigenesis via epigenetic mechanisms. Our study identified immune-related lncRNA (irlncRNA) pairs and compiled them into a set of noncoding gene signatures able to stratify subtypes of BRCA …
Long noncoding RNAs (lncRNAs) actively participate in breast cancer (BRCA) tumorigenesis via epigenetic mechanisms. Our study identif …
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort.
Peretti U, Cavaliere A, Niger M, Tortora G, Di Marco MC, Rodriquenz MG, Centonze F, Rapposelli IG, Giordano G, De Vita F, Stuppia L, Avallone A, Ratti M, Paratore C, Forti LG, Orsi G, Valente MM, Gaule M, Macchini M, Carrera P, Calzavara S, Simbolo M, Melisi D, De Braud F, Salvatore L, De Lorenzo S, Chiarazzo C, Falconi M, Cascinu S, Milella M, Reni M. Peretti U, et al. ESMO Open. 2021 Feb;6(1):100032. doi: 10.1016/j.esmoop.2020.100032. Epub 2021 Jan 4. ESMO Open. 2021. PMID: 33399070 Free PMC article.
MATERIALS AND METHODS: Patients of any age with pancreatic adenocarcinoma, screened within 3 months from diagnosis for gBRCApv in Italian oncologic centers systematically performing tests without any selection. For the purposes of our analysis, breast, ovarian, pancreas, a …
MATERIALS AND METHODS: Patients of any age with pancreatic adenocarcinoma, screened within 3 months from diagnosis for gBRCApv in Italian on …
Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.
Arun BK, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bell-McGuinn KM, Bach BA, Kundu MG, Ratajczak CK, Maag D, Diéras V. Arun BK, et al. Eur J Cancer. 2021 Sep;154:35-45. doi: 10.1016/j.ejca.2021.05.037. Epub 2021 Jul 6. Eur J Cancer. 2021. PMID: 34243076 Free article. Clinical Trial.
BACKGROUND: Addition of veliparib to carboplatin-paclitaxel, with continuation of veliparib monotherapy if carboplatin-paclitaxel was discontinued, improved progression-free survival (PFS) in patients with germline BRCA-associated locally advanced/metastatic …
BACKGROUND: Addition of veliparib to carboplatin-paclitaxel, with continuation of veliparib monotherapy if carboplatin-paclitaxel was discon …
Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
Sella T, Gal Yam EN, Levanon K, Rotenberg TS, Gadot M, Kuchuk I, Molho RB, Itai A, Modiano TM, Gold R, Kaufman B, Shimon SP. Sella T, et al. Breast. 2018 Aug;40:141-146. doi: 10.1016/j.breast.2018.05.007. Epub 2018 May 22. Breast. 2018. PMID: 29800932
Indices of tolerability and pCR were evaluated and compared to a historical cohort (n = 76) treated with ddAC-T. A secondary objective was to evaluate the rates of pCR by BRCA status. ...Overall pCR was 51.2%; 44.8% in BRCA wild-type compared to 64.3% in BRCA-ass …
Indices of tolerability and pCR were evaluated and compared to a historical cohort (n = 76) treated with ddAC-T. A secondary objectiv …
14 results